URL has been copied successfully!
enGene Therapeutics Inc. (NASDAQ:ENGN) shares are trading sharply lower Friday.
The decline follows the company’s Thursday announcement of updated interim results from its Phase 2 LEGEND trial. A wave of analyst downgrades on Friday morning has fueled the sell-off. The stock has fallen more than 80% since the results were released.
Clinical Efficacy vs. Durability Concerns
The trial evaluated detalimogene in patients with high-risk, BCG-unresponsive bladder cancer. Data as of April 21 showed a 54% complete response (CR) rate at any time. However, the Kaplan-Meier estimate for the 12-month CR rate was 25%.
Among …
Please follow us:
This post was originally published here
